December 26, 2025 (BOSTON, Mass.) – GE HealthCare has won FDA premarket authorization for Pristina Recon DL, a deep‑learning‑powered 3D mammography image reconstruction technology designed to significantly enhance breast imaging quality and support earlier cancer detection. This regulatory milestone highlights GE HealthCare’s innovation in AI‑enabled medical imaging and reinforces its leadership in advancing diagnostic tools for women’s health.
“By applying advanced deep learning technologies, we’re shaping the future of breast imaging — one defined by uncompromised image quality, faster workflows, and greater confidence in early cancer detection,” said Jyoti Gupta, PhD, president and CEO of Women’s Health and X‑ray at GE HealthCare.
Pristina Recon DL combines two sequential deep learning models to reduce noise and artifacts while producing high‑fidelity 3D tomosynthesis volumes and clearer synthesized 2D views — all without increasing radiation dose. Early assessments show radiologists prefer the AI‑enhanced images for sharper detail and improved diagnostic confidence.
The technology integrates with GE’s existing mammography platforms and is expected to streamline clinical workflows by delivering faster image reconstruction, personalized protocols, and enhanced visualization — helping clinicians detect subtle abnormalities that might be challenging with conventional methods.
Key Points:
- FDA Premarket Authorization granted for Pristina Recon DL, a deep learning‑based 3D mammography reconstruction system.
- Uses two sequential deep learning models to improve image clarity and reduce noise/artifacts without extra radiation.
- Offers enhanced diagnostic confidence, with radiologists preferring AI‑enhanced images in clinical reviews.
- Designed to streamline workflows with fast reconstruction, personalized protocols, and high‑quality visualization.
- Represents a significant advancement in AI‑enabled mammography and supports earlier detection of breast cancer.
